The purpose of this study is to evaluate high and low dose mazindol for cocaine abuse.
..Date First Received: September 20, 1999
Last Updated: June 23, 2005
Verified by: National Institute on Drug Abuse (NIDA), December 2002
Clinical Trial Phase: Phase 2 | Start Date:
Overall Status: Completed
Estimated Enrollment: 0
Brief Summary
Official Title: “Mazindol for Cocaine Abuse”
Condition Keyword(s):
Intervention(s):
The purpose of this study is to evaluate high and low dose mazindol for cocaine abuse.
Study Type: Interventional
Study Design: Treatment
Intervention(s) in this Clinical Trial
- Drug: Mazindol
Outcome Measures for this Clinical Trial
Primary Measures
- Side effects
- Drug use
- Retention
Criteria for Participation in this Clinical Trial
- Please contact site for information.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: National Institute on Drug Abuse (NIDA)
Overall Clinical Trial Officials and Contacts
Thomas R Kosten, M.D. Principal Investigator VA Connecticut Healthcare System
Additional Information
Information obtained from ClinicalTrials.gov on August 27, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00000277
Study ID Number: NIDA-09250-2
ClinicalTrials.gov Identifier: NCT00000277
Health Authority: United States: Federal Government
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
